Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 828

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer

Open access
Drilon, Alexander, Oxnard, Geoffrey R., Tan, Daniel S.W., Loong, Herbert H.F., Johnson, Melissa, Gainor, Justin, McCoach, Caroline E., Gautschi, Oliver, Besse, Benjamin, Cho, Byoung C., Peled, Nir, Weiss, Jared, Kim, Yu-Jung, Ohe, Yuichiro, Nishio, Makoto, Park, Keunchil, Patel, Jyoti, Seto, Takashi, Sakamoto, Tomohiro, Rosen, Ezra, Shah, Manisha H., Barlesi, Fabrice, Cassier, Philippe A., Bazhenova, Lyudmila, De Braud, Filippo, Garralda, Elena, Velcheti, Vamsidhar, Satouchi, Miyako, Ohashi, Kadoaki, Pennell, Nathan A., Reckamp, Karen L., Dy, Grace K., Wolf, Jürgen, Solomon, Benjamin, Falchook, Gerald, Ebata, Kevin, Nguyen, Michele, Nair, Binoj, Zhu, Edward Y., Yang, Luxi, Huang, Xin, Olek, Elizabeth, Rothenberg, S. Michael, Goto, Koichi, Subbiah, Vivek·2020·New England Journal of Medicine
DOI 10.1056/nejmoa2005653
Open this paper in CoChat — free account

Abstract

BACKGROUND: fusion-positive NSCLC, the efficacy and safety of selective RET inhibition are unknown. METHODS: fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated separately in a phase 1-2 trial of selpercatinib. The primary end point was an objective response (a complete or partial response) as determined by an independent review committee. Secondary end points included the duration of response, progression-free survival, and safety. RESULTS: fusion-positive NSCLC who had previously received at least platinum-based chemotherapy, the percentage with an objective response was 64% (95% confidence interval [CI], 54 to 73). The median duration of response was 17.5 months (95% CI, 12.0 to could not be evaluated), and 63% of the responses were ongoing at a median follow-up of 12.1 months. Among 39 previously untreated patients, the percentage with an objective response was 85% (95% CI, 70 to 94), and 90% of the responses were ongoing at 6 months. Among 11 patients with measurable central nervous system metastasis at enrollment, the percentage with an objective intracranial response was 91% (95% CI, 59 to 100). The most common adverse events of grade 3 or higher were hypertension (in 14% of the patients), an increased alanine aminotransferase level (in 12%), an increased aspartate aminotransferase level (in 10%), hyponatremia (in 6%), and lymphopenia (in 6%). A total of 12 of 531 patients (2%) discontinued selpercatinib because of a drug-related adverse event. CONCLUSIONS: fusion-positive NSCLC who had previously received platinum-based chemotherapy and those who were previously untreated. (Funded by Loxo Oncology and others; LIBRETTO-001 ClinicalTrials.gov number, NCT03157128.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa2005653

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 828

Metadata

Authors
Drilon, A., Oxnard, G. R., Tan, D. S. W., Loong, H. H. F., Johnson, M., Gainor, J., McCoach, C. E., Gautschi, O., Besse, B., Cho, B. C., Peled, N., Weiss, J., Kim, Y.-J., Ohe, Y., Nishio, M., Park, K., Patel, J., Seto, T., Sakamoto, T., Rosen, E., Shah, M. H., Barlesi, F., Cassier, P. A., Bazhenova, L., De Braud, F., Garralda, E., Velcheti, V., Satouchi, M., Ohashi, K., Pennell, N. A., Reckamp, K. L., Dy, G. K., Wolf, J., Solomon, B., Falchook, G., Ebata, K., Nguyen, M., Nair, B., Zhu, E. Y., Yang, L., Huang, X., Olek, E., Rothenberg, S. M., Goto, K., & Subbiah, V.
Venue
New England Journal of Medicine
Publisher
Massachusetts Medical Society
Published
2020-08-27
Volume
383
Issue
9
Pages
813-824
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
DOI
10.1056/nejmoa2005653
OpenAlex
W3081278682
Cited by
828
References
4
FWCI
64.15
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.